Yorvipath approved in Australia for chronic hypoparathyroidism
Yorvipath (palopegteriparatide) has been approved in Australia as a parathyroid hormone (PTH) replacement therapy for adults with chronic hypoparathyroidism. The news follows similar approvals in the European Union in 2023, and in the U.S. last year. Yorvipath will be made available in Australia through Specialised Therapeutics, under…